Provided by Tiger Trade Technology Pte. Ltd.

MABPHARM-B

0.435
0.000
Volume:- -
Turnover:- -
Market Cap:1.79B
PE:37.28
High:0.435
Open:0.435
Low:0.435
Close:0.435
52wk High:0.870
52wk Low:0.310
Shares:4.12B
HK Float Shares:4.12B
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.012
ROE:46.40%
ROA:0.28%
PB:9.77
PE(LYR):37.28
PS:2.38

Loading ...

MABPHARM-B Posts Stable Share Capital in July 2026; Confirms Compliance with 25% Public Float

Bulletin Express
·
Aug 04

Mabpharm-B Adopts Third Amended & Restated Memorandum and Articles, Sets New Governance Framework

Bulletin Express
·
Jun 26

Mabpharm gains NMPA clearance for CMAB807X denosumab injection, paving way for broader oncology-related revenue

Bulletin Express
·
Jun 24

Mabpharm-B Receives Approval for CMAB807X Leshu® (Denosumab Injection) Marketing Application

Stock News
·
Jun 24

Mabpharm Says NMPA Approves Cmab807x (denosumab Injection) NDA

Reuters
·
Jun 24

Mabpharm - Nmpa Approves Cmab807x (denosumab Injection) Nda

THOMSON REUTERS
·
Jun 24

BRIEF-Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA

Reuters
·
Jun 09

Mabpharm's Application for Osteoporosis Drug Approved in China

MT Newswires Live
·
Jun 09

Mabpharm secures NMPA approval for CMAB807 denosumab injection, marking its fourth commercialised biologic

Bulletin Express
·
Jun 09

Mabpharm-B Receives NMPA Approval for CMAB807, Its Denosumab Biosimilar

Stock News
·
Jun 09

Mabpharm says China NMPA approves denosumab injection CMAB807 for osteoporosis

Reuters
·
Jun 09

Mabpharm - Nmpa Approves Cmab807 (Denosumab Injection) Nda

THOMSON REUTERS
·
Jun 09

Mabpharm: No Share Capital Movements Recorded in May 2026 Monthly Return

Bulletin Express
·
Jun 02

Mabpharm-B Maintains 4.12 Billion Issued Shares in April 2026; 72.67 Million Options Remain Outstanding

Bulletin Express
·
May 06

MABPHARM-B 2025财年营收大涨并实现扭亏为盈,聚焦核心抗体研发与全球拓展

Bulletin Express
·
Apr 27

Mabpharm announces annual general meeting

Reuters
·
Apr 27

Mabpharm Schedules 26 June 2026 AGM to Approve 2025 Results, Board Re-elections, Dual Share Mandates and New Articles

Bulletin Express
·
Apr 27

Mabpharm to Convene 26 June 2026 AGM; Board Seeks 10% Share Buyback and 20% Issuance Mandates

Bulletin Express
·
Apr 27

Mabpharm publishes 2025 annual report

Reuters
·
Apr 27

Mabpharm-B Monthly Return Indicates Unchanged Share Structure for March 2026

Bulletin Express
·
Apr 02